Ana Komparic |
-
04.07.2022-27.07.2022
Beyond the State: Mapping the Ethical and Political Terrain of Private Sector Involvement in Health Care and Public Health
-
03.02.2020-16.03.2020
Beyond the State: Mapping the Ethical and Political Terrain of Private Sector Involvement in Health Care and Public Health
This project has three primary substantive objectives, described here, and several related outcomes, discussed in the subsequent section. The three primary substantive objectives are: (1) to contribute to the public and global health ethics literature by furthering the conceptual and theoretical understanding of the ethical and political issues related to private sector involvement and public-private interactions in health; (2) to begin to bridge relevant public and global health ethics literature with business ethics literature to identify where these two bodies of scholarship, which have historically had little cross-discussion, may inform one another to better conceptualize the ethical foundations for evaluating and informing private sector involvement in health; and (3) to explore the implications of private enterprise in health care and public health on ongoing debates in public and global health ethics literature pertaining to the role of liberalism, communitarianism, and solidarity in providing the moral and political foundations for stakeholder action and institutional involvement in matters related to health.
Within the first objective, the project will contribute to understanding the ethical issues and providing ethical guidance in the two case study areas: the fair pricing of medicines and the use and governance of big data and AI in health. The topics of these case studies are themselves areas of significant interest and scholarship. Thus, examining the two case studies will contribute to these unique areas by clarifying the normative foundations of decision-making, particularly around the legitimate scope, ends, and obligations of private sector stakeholders, which can be relevant for policy makers and scholars working pharmaceutical policy and data and AI governance.